Collegium Pharmaceutical Q3 net income falls 31% to $21.76 million
COLL•Collegium Pharmaceutical’s third-quarter 2026 GAAP net income fell 31% year over year to $21.8 million, while net revenues rose to $216.3 million. The company reaffirmed its full-year revenue guidance of $825 million to $855 million.
1. Quarterly results
Third-quarter 2026 net revenues rose to $216.3 million. JORNAY PM revenue climbed 24% year over year to $51.9 million, while pain portfolio revenue fell 18% to $138 million.
2. Outlook and buyback
Collegium reaffirmed its full-year 2026 net revenue guidance of $825 million to $855 million. Its $50 million accelerated share repurchase program is expected to settle in the fourth quarter of 2026.
